PHAT

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,382,176

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-036301 · tm219729-1_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,115,008

F1 · balance_after: Following the reported transactions, the RA Capital Healthcare Fund, L.P. (the "Fund") held 2,639,709 shares and a separately managed account (the "Account") held 475,299 shares.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,423,874

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.57 to $50.29. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,425,676

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.53 to $47.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,433,520

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.53 to $48.52. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 7

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 794,700

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.81 to $46.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 6

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 796,770

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 5

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 798,370

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.66 to $46.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 798,394

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $44.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 3

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 803,227

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $46.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 2

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 803,827

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.96. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 805,375

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 9

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,435,945

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $45.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 8

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,438,029

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.90. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 7

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,439,910

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,440,929

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.81 to $47.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,442,346

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.80 to $46.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,449,587

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.755. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,461,069

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.26 to $48.22. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,479,385

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.26 to $47.25. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,500,745

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.26 to $46.24. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 3

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 809,200

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 2

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 815,584

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.86 to $40.85. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 818,284

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.87. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-006094 · doc4.xml · derivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-21-006095 · doc4.xml · derivative · entry 1

Branning Todd P. · CIK 0001765274 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-21-006106 · doc4.xml · derivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common stock · 150,000 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,532,945

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.97 to $36.54. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,553,036

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.97 to $35.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,560,110

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.48 to $35.32. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 7

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,572,945

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,573,045

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,585,960

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,621,157

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,621,357

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.74 to $48.71. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,634,311

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.74 to $47.7308. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,647,603

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.72 to $46.70. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 838,200

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.42 to $45.73. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 3

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 841,195

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.41. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 2

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 845,502

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.65 to $44.97. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 847,330

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.50. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-010174 · doc5.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,505,945

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 9

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,652,603

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.95 to $40.90. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 8

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,653,506

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 7

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,656,860

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.71 to $38.70. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,659,480

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,664,081

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.75. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,668,682

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,676,562

SEC source: 0001209191-20-057921 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,676,662

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $43.29. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.